Amylin: Pharmacology, Physiology, and Clinical Potential

doi:10.1124/pr.115.010629

Paper

Amylin: Pharmacology, Physiology, and Clinical Potential

Published Jul 1, 2015 · D. Hay, Steve Chen, T. Lutz

Pharmacological Reviews

Q1 SJR score

291

Citations

12

Influential Citations

Full textSemantic Scholar

Abstract

Amylin is a pancreatic β-cell hormone that produces effects in several different organ systems. Here, we review the literature in rodents and in humans on amylin research since its discovery as a hormone about 25 years ago. Amylin is a 37-amino-acid peptide that activates its specific receptors, which are multisubunit G protein–coupled receptors resulting from the coexpression of a core receptor protein with receptor activity–modifying proteins, resulting in multiple receptor subtypes. Amylin’s major role is as a glucoregulatory hormone, and it is an important regulator of energy metabolism in health and disease. Other amylin actions have also been reported, such as on the cardiovascular system or on bone. Amylin acts principally in the circumventricular organs of the central nervous system and functionally interacts with other metabolically active hormones such as cholecystokinin, leptin, and estradiol. The amylin-based peptide, pramlintide, is used clinically to treat type 1 and type 2 diabetes. Clinical studies in obesity have shown that amylin agonists could also be useful for weight loss, especially in combination with other agents.

Literature Review

Highly Cited

Study Snapshot

Amylin is a pancreatic -cell hormone that plays a crucial role in regulating energy metabolism, and its agonists show potential for treating type 1 and type 2 diabetes and obesity.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Amylin: Pharmacology, Physiology, and Clinical Potential

Sign up to use Study Snapshot

References

Structural Basis for Receptor Activity-Modifying Protein-Dependent Selective Peptide Recognition by a G Protein-Coupled Receptor

The crystal structures reveal how receptor activity-modifying proteins (RAMP1-3) selectively recognize peptides, potentially informing drug development targeting CLR:RAMP complexes.

Cooperative interaction between leptin and amylin signaling in the ventral tegmental area for the control of food intake.

The ventral tegmental area (VTA) mediates the interaction of amylin and leptin to cooperatively promote negative energy balance and reduce food intake.

A second trigeminal CGRP receptor: function and expression of the AMY1 receptor

The AMY1 receptor, a potential migraine drug target, is expressed and functionally active in the sensory trigeminal system, suggesting potential for migraine treatment.

Liraglutide and obesity: a review of the data so far

Liraglutide, a GLP-1 receptor agonist, effectively reduces and sustains body weight loss in clinical trials, offering a less invasive alternative to bariatric surgery.

Islet amyloid polypeptide exerts a novel autocrine action in β‐cell signaling and proliferation

Islet amyloid polypeptide (IAPP) plays a key role in pancreatic cells' response to glucose through an autocrine mechanism, affecting signaling and proliferation depending on glucose concentration.

Citations

The role of amylin, a gut–brain axis hormone, in metabolic and neurological disorders

Amylin plays a role in metabolic and neurological disorders, making it a potential target for therapeutic approaches.

Dysregulation of Metabolic Peptides Precedes Hyperinsulinemia and Inflammation Following Exposure to Rotenone in Rats

Rotenone exposure disrupts metabolic homeostasis in rats, leading to obesity and hyperinsulinemia, potentially affecting long-term health.

Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis.

Atogepant, a preventive migraine treatment, is associated with modest dose- and duration-dependent weight loss in adults with migraines.

Peptide discovery across the spectrum of neuroinflammation; microglia and astrocyte phenotypical targeting, mediation, and mechanistic understanding

Peptides targeting microglia and astroglia phenotypes can mediate deleterious behaviors or promote beneficial outcomes in neuroinflammation.

Intranasal administration of dextran-pramlintide polyelectrolyte complex-coated nanoemulsions improves cognitive impairments in a mouse model of Alzheimer's disease.

Intranasal Pramlintide administration improves cognitive impairments in a mouse model of Alzheimer's disease, but does not affect anhedonic behavior, oxidative stress, or pre-synaptic SNAP-25 and post-synaptic PSD-95 levels.

Analyzing Amylin Aggregation Inhibition Through Quantum Dot Fluorescence Imaging

Quantum dot fluorescence imaging reveals that rosmarinic acid, a polyphenol, inhibits amylin aggregation, potentially aiding in the treatment and prevention of amylin-related diseases.

Modulation of amylin and calcitonin receptor activation by hybrid peptides

Hybrid peptides made from rat amylin and salmon calcitonin significantly changed the potency for amylin and calcitonin receptor activation, providing insights into the role of peptide C-terminal fragments in modulating these receptors.

Development of the novel amylin and calcitonin receptor activators by peptide mutagenesis.

Novel amylin and calcitonin receptor activators developed through peptide mutagenesis show higher potency for activation than currently available treatments, potentially benefiting obesity treatment.